(Q52973899)

10 May 2018

title

Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. (English)

1 reference

10 May 2018

author name string

Goessl C

1

1 reference

10 May 2018

Sauter T

2

1 reference

10 May 2018

Michael T

3

1 reference

10 May 2018

Bergé B

4

1 reference

10 May 2018

Staehler M

5

1 reference

10 May 2018

Miller K

6

1 reference

10 May 2018

language of work or name

English

0 references

publication date

1 March 2000

1 reference

10 May 2018

published in

Urology

1 reference

10 May 2018

volume

55

1 reference

10 May 2018

issue

3

1 reference

10 May 2018

page(s)

414-418

1 reference

10 May 2018

Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

The Use of Intravesical Oxybutynin Chloride in Children with Neurogenic Bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Tolterodine--a new bladder-selective antimuscarinic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Toward a new classification of overactive bladders

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Oxybutynin Chloride Combined with Intermittent Clean Catheterization in the Treatment of Myelomeningocele Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

The effect of intravesical pressure on glomerular filtration rate in patients with myelomeningocele

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Oxybutinin and the prevention of urinary incontinence in spina bifida

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900477-X

7 January 2021

10.1016/S0090-4295(99)00477-X

Identifiers

DOI

1 reference

10 May 2018

1 reference

10 May 2018